Child Neurology: Pathologically Confirmed Thrombotic Microangiopathy Caused by Onasemnogene Abeparvovec Treatment for SMA
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy for spinal muscular atrophy (SMA). Although several cases of drug-induced thrombotic microangiopathy due to onasemnogene abeparvovec have been reported, none has been confirmed pathologically. Here, we present renal histopathologic findings of TMA due to onasemnogene abeparvovec. On day 5 after receiving onasemnogene abeparvovec, a 23-month-old girl with SMA type 1 developed thrombocytopenia, microangiopathic hemolytic anemia, liver dysfunction, acute kidney injury, and hypertension. She was diagnosed with TMA and received an increased dose of prednisolone, antihypertensives, diuretics, packed red blood cell and platelet transfusion, a single dose of eculizumab, 4 cycles of plasmapheresis, and intermittent and continuous hemodialysis. Her TMA resolved by day 30. On day 49, renal biopsy was performed. Light microscopy revealed proliferation of glomerular mesangial cells and matrix, with mesangiolysis, endothelial cell swelling, and partial double contours of the glomerular basement membrane. Electron microscopy showed endothelial injury, with edematous changes of the subendothelial spaces and neoformation of the basement membrane, without electron-dense depositions. These findings are compatible with the recovery phase of TMA. One year after drug administration, her motor function is improved. She can hold her posture against gravity and has neither dysphagia nor respiratory disturbance, but mild hypertension persists. Physicians should be vigilant regarding TMA as a severe side effect of onasemnogene abeparvovec treatment, especially when thrombocytopenia, hemolytic anemia, increased lactate dehydrogenase, or acute kidney injury is present.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, the complement arm of the immune system has been implemented in recent fatalities in high-dose systemic AAV administration in patients.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [14]
Citations
Cites
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208981 · Cited by 1,586 · cited 7×
“Immune responses to infection might have triggered the development of TMA.”
MethodInfluentialSyndromes of Thrombotic Microangiopathy
George, J. N., & Nester, C. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1312353 · Cited by 1,279
Finkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J. W., Montes, J., De Vivo, D. C., Yamashita, M., Rigo, F., Hung, G., Schneider, E., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31408-8 · Cited by 1,019 · cited 1×
“In 2016, the Food and Drug Administration (FDA) approved nusinersen, an antisense oligonucleotide.(7) In 2020, risdiplam, another small molecule, received FDA approval.”
BackgroundObservational study of spinal muscular atrophy type I and implications for clinical trials
Finkel, R. S., McDermott, M. P., Kaufmann, P., Darras, B. T., Chung, W. K., Sproule, D. M., Kang, P. B., Foley, A. R., Yang, M. L., Martens, W. B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000741 · Cited by 528 · cited 1×
“The majority of SMA1-affected infants require feeding and ventilatory support by age 14 months and have a life expectancy of less than 2 years without intervention.(6) In 2016, the Food and Drug Administration (FDA) approved nusinersen, an antisense oligonucleotide.”
BackgroundRisdiplam in Type 1 Spinal Muscular Atrophy
Baranello, G., Darras, B. T., Day, J. W., Deconinck, N., Klein, A., Masson, R., Mercuri, E., Rose, K., El-Khairi, M., Gerber, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2009965 · Cited by 436 · cited 1×
“In 2020, risdiplam, another small molecule, received FDA approval.(8) Onasemnogene abeparvovec, which was approved by the FDA in 2019, is an adeno-associated virus (AAV) vector-based gene therapy for SMA.”
BackgroundDrug-induced thrombotic microangiopathy: a systematic review of published reports
Al-Nouri, Z. L., Reese, J. A., Terrell, D. R., Vesely, S. K., & George, J. N. (2015) · Blood · doi:10.1182/blood-2014-11-611335 · Cited by 367 · cited 1×
“DITMA has been classified into 2 categories: immune mediated and toxicity mediated.(13) The former leads rapidly to renal failure, whereas the latter has a course lasting over several weeks or months.”
BackgroundChand, D. H., Zaidman, C., Arya, K., Millner, R., Farrar, M. A., Mackie, F. E., Goedeker, N. L., Dharnidharka, V. R., Dandamudi, R., & Reyna, S. P. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.11.054 · Cited by 210 · cited 2×
“Two of the 3 previous cases were treated with nusinersen before onasemnogene abeparvovec.(12) Whether the preliminary administration of nusinersen in our patient led to a drug interaction with onasemnogene abeparvovec is unclear.”
BackgroundResultGlanzman, A. M., McDermott, M. P., Montes, J., Martens, W. B., Flickinger, J., Riley, S., Quigley, J., Dunaway, S., O'Hagen, J., Deng, L., et al. (2011) · Pediatric Physical Therapy · doi:10.1097/pep.0b013e3182351f04 · Cited by 159
Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes
Waldrop, M. A., Karingada, C., Storey, M. A., Powers, B. R., Iammarino, M. A., Miller, N. F., Alfano, L. N., Noritz, G. H., Rossman, I. T., Ginsberg, M., et al. (2020) · PEDIATRICS · doi:10.1542/peds.2020-0729 · Cited by 137 · cited 3×
“Well-known side effects of the drug are fever, vomiting, acute liver injury, transient thrombocytopenia, and increased troponin I.(9)”
BackgroundInfluentialSubacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1
Feldman, A. G., Parsons, J. A., Dutmer, C. M., Veerapandiyan, A., Hafberg, E., Maloney, N., & Mack, C. L. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.05.044 · Cited by 136
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“412,413,477 It is not known what factors could cause the predisposition to TMA after rAAV administration.”
BackgroundCurrent clinical applications of AAV-mediated gene therapy
Byrne, B. J., Flanigan, K. M., Matesanz, S. E., Finkel, R. S., Waldrop, M. A., D'Ambrosio, E. S., Johnson, N. E., Smith, B. K., Bönnemann, C. G., Carrig, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.045 · Cited by 162
“19,78,79 Uncommonly, patients have suffered from severe and even fatal super-infection from other viruses when immunosup-pressed with prednisone.”
Innate immune sensing of adeno-associated virus vectors
Cao, D., Byrne, B. J., de Jong, Y. P., Terhorst, C., Duan, D., Herzog, R. W., & Kumar, S. R. P. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.040 · Cited by 50
Pane, M., Berti, B., Capasso, A., Coratti, G., Varone, A., D’Amico, A., Messina, S., Masson, R., Sansone, V., Donati, M. A., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101997 · Cited by 50
“We did not observe any of the major serious adverse effects recently reported such as TMA 10,19,27,28 or liver failure, 19,20 irrespective of age or previous treatment.”
Complement System Response to Adeno-Associated Virus Vector Gene Therapy
Kropf, E., Markusic, D. M., Majowicz, A., Mingozzi, F., & Kuranda, K. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.194 · Cited by 39
Metadata
- Authors
- Yazaki, K., Sakuma, S., Hikita, N., Fujimaru, R., & Hamazaki, T.
- Affiliations
- Osaka City General Hospital (JP)
- ORCID
- Hikita, Norikatsu
- Venue
- Neurology
- Published
- 2022-05-10
- Volume
- 98
- Issue
- 19
- Pages
- 808-813
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W4220839454
- Cited by
- 31
- References
- 15
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 7 · 2023: 8 · 2022: 3
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- thrombotic microangiopathy, onasemnogene abeparvovec, spinal muscular atrophy type 1, adeno-associated virus vectors, kidney histopathology, acute kidney injury, microangiopathic hemolytic anemia, thrombocytopenia, endothelial injury, pediatric patients
- MeSH terms
- Anemia, Female, Humans, Hypertension, Infant, Muscular Atrophy, Spinal, Neurology, Thrombotic Microangiopathies, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Child Neurology: Pathologically Confirmed Thrombotic Microangiopathy Caused by Onasemnogene Abeparvovec Treatment for SMA. https://app.cochat.ai/papers/10.1212/wnl.0000000000200676
- The paper
- Yazaki, K., Sakuma, S., Hikita, N., Fujimaru, R., & Hamazaki, T. (2022). Child Neurology: Pathologically Confirmed Thrombotic Microangiopathy Caused by Onasemnogene Abeparvovec Treatment for SMA. Neurology. https://doi.org/10.1212/wnl.0000000000200676
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.